Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors sterna biologicals
- 17 May 2015 According to Sterna Biologics media release, results of this other two Phase I trials (see profile 209662 and 214949) were published in the 2015 Journal of Allergy and Clinical Immunology.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.